
ARGX
Healthcare · Biotechnology · $60.37B market cap
$960.04-21.29 (-2.2%)Nov 13, 4:00 PM EST
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · -9.2% over 90 days · 30-day revisions 0 up, 1 down
Beat estimates in 4 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Oct 22, 2026 | Before the open | 7.44 | 7.80 | +4.8% |
| Jul 23, 2026 | Before the open | 6.13 | 7.32 | +19.4% |
| May 7, 2026 | Before the open | 4.92 | 5.52 | +12.2% |
| Feb 26, 2026 | Time not confirmed | 6.24 | 8.02 | +28.5% |
| Oct 30, 2025 | Before the open | 4.16 | 5.18 | +24.5% |
| Jul 31, 2025 | Before the open | 3.02 | 3.74 | +23.8% |
| May 8, 2025 | Before the open | 2.31 | 2.58 | +11.7% |
| Feb 27, 2025 | Before the open | 1.70 | 0.71 | -58.0% |
| Oct 31, 2024 | Before the open | 0.06 | 1.39 | +2216.7% |
| Jul 25, 2024 | Before the open | -1.07 | 0.45 | +142.1% |
| May 9, 2024 | Before the open | -0.87 | -1.04 | -19.5% |
| Feb 29, 2024 | Before the open | -1.70 | -1.68 | +1.2% |
| Oct 31, 2023 | Before the open | -1.45 | -1.25 |
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for…
| +13.8% |
| Jul 27, 2023 | Before the open | -1.86 | -1.69 | +9.1% |
| May 4, 2023 | Before the open | -2.28 | -0.52 | +77.2% |
| Mar 2, 2023 | Time not confirmed | -0.70 | -0.70 | 0.0% |
| Oct 27, 2022 | Before the open | -3.58 | -4.26 | -19.0% |
| Jul 28, 2022 | Before the open | -4.72 | -3.81 | +19.3% |
| May 5, 2022 | Before the open | -5.10 | -4.36 | +14.5% |
| Mar 3, 2022 | Before the open | -4.81 | -5.06 | -5.2% |
| Oct 28, 2021 | Before the open | -4.58 | -2.53 | +44.8% |
| Jul 29, 2021 | Before the open | -3.23 | 1.98 | +161.3% |
| May 14, 2021 | Before the open | -2.83 | -0.81 | +71.4% |
| Mar 4, 2021 | Before the open | -2.64 | -3.53 | -33.7% |
| Oct 22, 2020 | Before the open | -2.78 | -4.01 | -44.2% |
| Jul 31, 2020 | Before the open | -2.51 | -3.38 | -34.7% |
| May 14, 2020 | Before the open | -1.79 | -2.02 | -12.8% |
| Feb 29, 2020 | Before the open | -1.38 | -2.37 | -71.7% |
| Oct 24, 2019 | Before the open | -1.05 | -0.73 | +30.5% |
| Aug 1, 2019 | Before the open | -0.88 | -1.54 | -75.0% |
| May 9, 2019 | Before the open | -0.77 | -0.67 | +13.0% |
| Feb 28, 2019 | After the close | -0.65 | -0.90 | -38.5% |
| Oct 24, 2018 | After the close | -0.77 | -0.66 | +14.3% |
| Aug 2, 2018 | Before the open | -0.48 | -0.07 | +85.4% |
| May 9, 2018 | Before the open | -0.22 | -0.81 | -268.2% |
| Mar 1, 2018 | Before the open | -0.35 | -0.41 | -17.1% |